RecruitingPhase 3NCT06698796
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
Studying Dermatomyositis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pfizer
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- Dazukibart(drug)
- Enrollment
- 211 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (21)
- AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Glendale, Glendale, Arizona, United States
- Arthritis & Rheumatology Research Institute, PLLC, Allen, Texas, United States
- Nerve & Muscle Center of Texas, Houston, Texas, United States
- Rheumatology & Pulmonary Clinic, Beckley, West Virginia, United States
- Centro de Investigaciones Médicas Tucuman, SAN M. de Tucuman, Tucumán Province, Argentina
- Medical Center Artmed, Plovdiv, Bulgaria
- Anhui Provincial Hospital, Hefei, Anhui, China
- The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
- Renji Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China
- First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
- Peking Union Medical College Hospital, Beijing, China
- Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary
- CHARM HEALTHCARE PRIVATE LIMITED (Previously Dr Shenoy's Care Private Limited), Ernākulam, Kerala, India
- Sheba Medical Center, Ramat Gan, Central District, Israel
- Institute of Science Tokyo Hospital, Bunkyo-ku, Tokyo, Japan
- +6 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06698796 on ClinicalTrials.govOther trials for Dermatomyositis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07111065FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)National Institute of Environmental Health Sciences (NIEHS)
- ACTIVE NOT RECRUITINGNCT07531446Construction of a Clinico-Imaging Collaborative Diagnostic Model for Dermatomyositis Combined With Interstitial Lung Disease Based on PET/CT Imaging Features and Clinical ParametersRuijin Hospital
- RECRUITINGPHASE2, PHASE3NCT07160205Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)Restem, LLC.
- RECRUITINGNANCT07377058RCT of Tocilizumab for Anti-MDA5+DMPeking Union Medical College Hospital
- RECRUITINGNCT07345949Panniculitis in DermatomyositisUniversity Hospital, Strasbourg, France
- RECRUITINGPHASE2NCT06857240Topical Ruxolitinib Cream for Refractory Cutaneous DermatomyositisThe Cleveland Clinic
- RECRUITINGPHASE1NCT06919380Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy TrialLi Shiyue
- RECRUITINGPHASE2NCT06672822Intralesional Injection of STS in Treatment of CalcinosisRobyn T. Domsic, MD, MPH